

REFERENCE

- Au, W. Y., Caguioa, P. B., Chuah, C. & Hsu, S. C., 2009. Chronic Myeloid Leukemia in Asia. *International Journal of Hematology*, 89(1), pp. 14-23.
- Baccarani, M. & Dreyling, M., 2010. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Anal of Oncology*, 21(5), pp. 165-167.
- Bagg, A., 2002. Chronic Myeloid Leukemia: A Minimalistic View of Post-Therapeutic Monitoring. *Journal of Molecular Diagnostics*, 4(1), pp. 1-10.
- Calabretta, B. & Perrotti, D., 2004. The biology of CML blast crisis. *Blood*, 103(11), pp. 4010-4022.
- Chang, J. S., Santhanan, R., Trotta, R. & Neviani, P., 2007. High levels of the BCR/ABL oncoprotein are required for the MAPK-hnRNP-E2-dependent suppression of C/EBP α -driven myeloid differentiation. *Blood*, 110(3), pp. 994-1002.
- Chantrain, C. F., Feron, O., Marbaix, E. & DeClerck, Y. A., 2008. Bone Marrow Microenvironment and Tumor Progression. *Cancer Microenvironment*, 1(1), pp. 23-35.
- Chasseriau, J., Rivet, J., Bilan, F. & Chomel, J., 2004. Characterization of the different BCR-ABL transcripts with a singel multiplex RT-PCR. *J Mol Diagn*, 6(4), pp. 343-347.

- Chereda, B. & Melo, J. V., 2016. The Biology and Pathogenesis of Chronic Myeloid Leukemia. In: R. Hehlmann, ed. *Hematologic Malignancies*. Switzerland: Springer International Publishing Switzerland, pp. 17-39.
- Druker, B., 2008. Translation of the Philadelphia chromosome into therapy for CML. *Blood*, 112(13), pp. 4808-4817.
- Elias, M., Baba, A., Azlan, H. & Rosline, H., 2014. BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patient - Frequency and clinical outcome. *Leuk Res*, 38(4), pp. 454-459.
- Elmaagacli, A., Beelen, D., Opalka, B. & Seeber, S., 2000. The amount of BCR-ABL fusion transcripts detected by the real-time quantitative polymerase chain reaction method in patients with Philadelphia chromosome positive chronic myeloid leukemia correlates with the disease stage. *Ann Hematol*, 79(8), pp. 424-431.
- Fisher, B. L., Lyons, R. M. & Sears, D. A., 1977. Development of chronic myelocytic leukemia during the course of acute lymphocytic leukemia in an adult. *American Journal of Hematology*, 2(3), pp. 291-297.
- Frazer, R., Irvine, A. E. & McMullin, M. F., 2007. Chronic Myeloid Leukaemia in the 21st Century. *Ulster Med J*, 76(1), pp. 8-17.
- Gracia-Manero, G. et al., 2003. Chronic myelogenous leukemia: A review and update of therapeutic strategies. *Cancer*, 98(3), pp. 437-451.

Handayani, W. & Baribowo, A. S., 2008. *Buku ajaran asuhan keperawatan pada klien dengan gangguan sistem hematologi*. 1 ed. Jakarta: Jakarta Salemba Medika 2008.

Haznedarađlu, I. C., 2013. Current Management of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors. *Turk J Hematol*, 30(3), pp. 247-255.

Höglund, M., Sandin, F. & Simonsson, B., 2015. Epidemiology of chronic myeloid leukaemia: an update. *Ann Hematol*, 94(2), pp. S241-S247.

Jabbour, E. & Kantaijian, H., 2014. Chronic myeloid leukemia: 2014 update on diagnosis, monitoring, and management. *Am J Hematol*, 89(5), pp. 547-556.

Kessenbrock, K., Plaks, V. & Werb, Z., 2010. Matrix Metalloproteinases: Regulators of the Tumor Microenvironment. *Cell*, 141(1), pp. 52-67.

Kotiah, S. D. & Besa, E. C., 2015. *Chronic Myelogenous Leukemia Staging*. [Online]

Available at: <http://emedicine.medscape.com/article/2006731-overview>

[Accessed 14 May 2016].

Nakahara, F. et al., 2014. Hes 1 promotes blast crisis in chronic myelogenous leukemia through MMP-9 upregulation in leukemic cells. *Blood*, 123(25), pp. 2932-2942.

National Center for Biotechnology Information, 2016. *Gene*. [Online]

Available at:

<http://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=ShowDetailView&TermToSearch=4318>

- O'Brien, S., Abboud, C. N., Akhtari, M. & Altman, J., 2012. Chronic Myelogenous Leukemia. *Journal of the National Comprehensive Cancer Network*, 10(1), pp. 64-110.
- Perrotti, D., Jamieson, C. & Goldman, J., 2010. Chronic myeloid Leukemia - mechanisms of blastic transformation. *The Journal of Clinical Investigation*, 120(7), pp. 2254-2264.
- Quintas-Cardama, A. & Cortes, J., 2009. Molecular biology of bcr-abl 1-positive chronic myeloid leukemia. *Blood*, 113(8), pp. 1619-1627.
- Ries, C., Loher, F., Zang, C. & Ismail, M. G., 1999. Matrix Metalloproteinase Production by Bone Marrow Mononuclear Cells from Normal Individuals and Patients with Acute and Chronic Myeloid Leukemia or Myelodysplastic Syndromes. *Clinical Cancer Research*, 5(5), pp. 1115-1124.
- Rumpold, H. & Webersinke, G., 2011. Molecular pathogenesis of Philadelphia-positive chronic myeloid leukemia - is it all BCR-ABL?. *Curr Cancer Drug Target*, 11(1), pp. 3-19.
- Salesse, S. & Verfaillie, C. M., 2002. BCR/ABL: from molecular mechanisms of leukemia induction to treatment of chronic myelogenous leukemia. *Oncogene*, 21(56), pp. 8547-8559.
- Sawyers, C. L., Hochhaus, A., Feldman, E. & Goldman, J. M., 2002. Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. *Blood*, 99(10), pp. 3530-3539.

- Shet, A., Jahagirdar, B. & Verfaillie, C., 2002. Chronic myelogenous leukemia: mechanisms underlying disease progression. *Leukemia*, 16(8), pp. 1402-1411.
- Siliaber, C., Mayerhofer, M., Agis, H. & Sagaster, V., 2003. Chronic myeloid leukaemia: pathophysiology, diagnostic parameters, and current treatment concepts. *Wien Klin Wochenschr*, 115(13-14), pp. 485-504.
- Skorski, T., 2012. Genetic mechanisms of chronic myeloid leukemia blastic transformation. *Curr Hematol Malig*, 7(2), pp. 87-93.
- Smith, D. L., Burthem, J. D. & Whetton, A. D., 2003. Molecular pathogenesis of chronic myeloid leukaemia. *Expert Rev Mol Med*, 5(27), pp. 1-27.
- Valent, P., Lion, T., D., W. & Sillaber, C., 2008. Diagnostic algorithms, monitoring, prognostication, and therapy in chronic myeloid leukemia (CML); a proposal of the Austrian CML platform. *Wien Klin Wochenschr*, 120(21-22), pp. 697-709.
- Yasmin, Wallace, S., McEniery, C. M. & Pusalkar, P., 2005. Matrix Metalloproteinase-9 (MMP-9), MMP-2, and Serum Elastase Activity are associated with systolic hypertension and arterial stiffness. *Arteriosclerosis, Thrombosis and Vascular Biology*, 25(4), pp. 372-378.
- Zhang, J., Lin, F., Chase, A. & Goldman, J. M., 1996. Comparison of genomic DNA and cDNA for detection of residual disease after treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation. *Blood*, 87(6), pp. 2588-2593.

Zhu, X. et al., 2011. TGF- β 1-induced PI3K/Akt/NF- κ B/MMP9 signalling pathway is activated in Philadelphia chromosome-positive chronic myeloid leukaemia hemangioblasts. *Journal of Biochemistry*, 149(405-414), pp. 406-414.